TwitterLinkedInFacebook Instagram
United StatesLanguage Flag



OraSure Technologies, Inc., transforms health through powerful insight by providing access to accurate, essential information. Together with its wholly-owned subsidiaries – DNA Genotek, Diversigen, and Novosanis – OraSure provides its customers with end-to-end solutions that encompass tools, services, and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, as well as molecular services solutions designed to discover and detect critical medical conditions.

OraSure’s first-to-market, innovative products include rapid tests for HIV, Hepatitis C, and COVID-19; sample self-collection and stabilization products for molecular applications; and oral fluid laboratory tests for detecting various drugs of abuse. The portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers.

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following